Structural basis for small molecule NDB as a selective antagonist of Farnesoid X receptor ( FXR ) in stabilizing the homodimerization of the receptor
Xing Xu,Xin Xu,Peng Liu,Zhi-yuan Zhu,Jing Chen,Hai-an Fu,Li-li Chen,Li-hong Hu,Xu Shen
2015-01-01
Abstract:Farnesoid X receptor (FXR) as a bile acid sensor plays potent roles in multiple metabolic processes, and its antagonist has recently revealed special interests in the treatment of metabolic disorders, although the underlying mechanisms still remain unclear. Here, we identified that the small molecule N-benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2, 6-dichloro-4-(dimethylamino) benzamide (NDB) functioned as a selective antagonist of hFXR, and crystal structure of hFXR ligand binding domain (hFXR-LBD) in complex with NDB was analyzed. It was unexpectedly discovered that NDB induced rearrangements of helix 11 (H11) and helix 12 (H12, AF-2) by forming a homodimer of hFXR-LBD, totally different from the active conformation in monomer state, and the binding details were further supported by the mutation analysis. Moreover, functional studies demonstrated that NDB effectively antagonized the GW4064-stimulated FXR/RXR http://www.jbc.org/cgi/doi/10.1074/jbc.M114.630475 The latest version is at JBC Papers in Press. Published on June 22, 2015 as Manuscript M114.630475 Copyright 2015 by The American Society for Biochemistry and Molecular Biology, Inc. at Y A L E U N IV E R IT Y on July 0, 2015 hp://w w w .jb.org/ D ow nladed from NDB stabilizes hFXR homodimerization 2 interaction and FXRα target gene expression in primary mouse hepatocytes, including the small heterodimer partner (SHP) and bile-salt export pump (BSEP), meanwhile administration of NDB to db/db mice efficiently decreased the gene expressions of phosphoenolpyruvate carboxykinase (PEPCK), glucose 6-phosphatase (G6-pase), SHP and BSEP. It is expected that our firstly analyzed crystal structure of hFXR-LBD/NDB will help expound the antagonistic mechanism of the receptor, and NDB may find its potential as a lead compound in anti-diabetes research. Farnesoid X receptor (FXR) is a bile acid (BA) activated nuclear receptor responsible for the regulation of the specific target genes involved in a broad spectrum of biological processes including bile acids, glucose and lipid homeostasis, liver regeneration, bacterial growth and tumor growth (1). FXR highly expresses in the liver, intestine, kidney and adrenals (2,3), and its modulator has revealed promising therapeutic potential against metabolic disorders. In most cases, FXR forms a heterodimer with retinoid X receptor (RXR) to modulate the expression of its target genes. Primary bile acids such as chenodeoxycholic acid (CDCA) and cholic acid (CA) have been identified as the endogenous ligands of this receptor (4). Bile acids as signaling molecules activate not only FXR, but also a cluster of receptors, such as the pregnane X receptor (PXR), vitamin D receptor (VDR), the constitutive androstane receptor (CAR) and the bile acid receptor TGR5 (5), and are toxic to cells at high concentrations. Thus, discovery of specific non-bile acid modulator of FXR is expected to be valuable in the regulation of the diverse metabolic pathways for treating the related metabolic disorders. In recent years, FXR agonists have been received much attention for the beneficial effects of FXR activation in lowering plasma lipogenesis, repressing very low density lipoprotein (VLDL) production, increasing plasma triglyceride (TG) clearance, improving insulin sensitivity and promoting the storage of glycogen (6). To date, increasing numbers of FXR agonists have been discovered, such as GW4064, fexaramine, 6a-ethyl-CDCA, MFA-1, XL335 and ivermectin (7-12). However, it was determined that FXR activation by full agonist may also cause undesired side effects in animals. For example, long-term treatment of GW4064 even accelerated obesity and exacerbated diabetes in diet-induced obesity mice through reduction of bile acid pool (13). In addition, agonists such as bile acids, GW4064 and XL335 reduced high density lipoprotein (HDL) cholesterol (14,15). By contrast, FXR blockage may find its beneficial effect on the improvement of hypercholesterolemia. For example, the natural product guggulsterone extracted from the guggul tree as an FXR antagonist FXR-dependently decreased hepatic cholesterol in mice fed with a high-cholesterol diet (16), and the nonsteroidal FXR antagonist 12u also functioned in lowering hepatic cholesterol in the high-cholesterol diet induced C57BL/6 mice (17). Moreover, the results from FXR-deficiency mice confirmed that FXR suppression showed potential effects on the improvement of obesity and diabetes (18-20). Additionally, AMP-activated protein kinase (AMPK) was recently identified as a co-regulator of FXR, and AMPK activator metformin as an anti-diabetic agent showed potently antagonistic effect on FXR (21). It is thus believed that discovery of selective antagonist of FXR will render special interests in anti-metabolic disorders research. In structure, similar to most of the other nuclear receptors (1), FXR is divided into several major domains: an N-terminal region containing a at Y A L E U N IV E R IT Y on July 0, 2015 hp://w w w .jb.org/ D ow nladed from NDB stabilizes hFXR homodimerization 3 ligand-independent transactivation function domain 1 (AF1), a highly conserved DNA binding domain (DBD), a hinge region linking DBD to the C-terminal LBD that contains also a strong transactivation function domain 2 (AF2). To date, dozens of the structures of FXR-LBD in complex with different agonists have been determined (7,10,12,22). The results indicated that in the active conformation of FXR, FXR-LBD folds into a canonical three-layer helical sandwich that embeds a hydrophobic pocket for ligand binding, and AF2 interacts with the coactivator, including steroid receptor coactivator-1 (SRC-1), SRC-2, SRC-3 and PPAR coactivator-1 (PGC-1). However, no data has been yet obtained concerning the molecular mechanism of FXR antagonism due to the lack of the structural information of either unliganded FXR (apo-LBD) or antagonist-bound FXR. In the current work, we determined the small molecule N-benzyl-N-(3-(tert-butyl)4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) benzamide (NDB, Fig. 1A) as a selective antagonist of hFXR, and the crystal structure of hFXR-LBD in complex with NDB was successfully analyzed. It was discovered that the binding of NDB caused an unusual rearrangement of H11 and H12 (AF-2) of the receptor by forming a homodimer of hFXR-LBD. The binding details between two hFXR-LBD monomers were also supported by the mutation analysis and co-repressor binding assay. Moreover, animal based assays have highlighted the potential of NDB in the prevention of glucose and lipid metabolism dysfunction. It is expected that our firstly analyzed crystal structure of hFXR-LBD binding to its antagonist NDB may help largely expound the antagonistic mechanism of the receptor, and NDB will find its potential as a lead compound in anti-diabetes research. EXPERIMENTAL PROCEDURES Materials-All reagents were of analytical grade. Dimethyl sulfoxide (DMSO), chenodeoxycholic acid (CDCA), GW4064 and Collagenase IV were purchased from Sigma. Reverse transcript reagents and SYBR Green PCR Master Mix were from Takara. Series S sensor chip CM5, EDC, NHS and ethanolamine HCl were from GE healthcare. Biotin-labeled SRC-1 peptide (Bio-SRC-1, Bio-CPSSHSSLTERHKILHRLLQEGSPS), Biotin-labeled SRC-2 peptide (Bio-SRC-2, Bio-SLTERHKILHRLLQEGSP), Biotin-labeled SRC-3 peptide (Bio-SRC-3, Bio-KENNALLRYLLDRDD), Biotin-labeled PGC-1 peptide (Bio-PGC-1, Bio-AEEPSLLKKLLLAP), Biotin-labeled NCoR-2 peptide (Biotin-NCoR-2, Bio-SFADPASNLGLEDIIRKALMGS) were synthesized by Shanghai Shenggong Biotechnology. The histidine detection kit for AlphaScreen assays was purchased from Perkin Elmer. Cell culture medium Williams’E medium, Dulbecco’s modified eagle medium (DMEM) and fetal bovine serum (FBS) were from Gibco. Dual-Luciferase Assay System kit was obtained from Promega. Anti-GST-Tb was purchased from Cisbio Bioassays. Animal experiments-Male C57BL/6J db/db mice at 8 weeks of age were fed with normal diet and i.p. injected with either vehicle or NDB (24mg/kg) once a day for 4 weeks. The animals were then killed after fasting overnight, and mice livers were collected and frozen in liquid nitrogen for real-time PCR. Cell cultures-The human hepatoma HepG2 and HEK293T cells were obtained from ATCC (Manassas, VA, USA). Primary mouse hepatocytes were isolated from male C57/BL6 mice in 8-12 weeks of age (Shanghai SLAC Laboratory Animal Co. Ltd) using a two-step collagenase perfusion at Y A L E U N IV E R IT Y on July 0, 2015 hp://w w w .jb.org/ D ow nladed from NDB stabilizes hFXR homodimerization 4 and low speed centrifugation (23). Cells were washed and suspended in Williams' E medium supplemented with 10% FBS, 100 U/ml penicillin and 100 g/ml streptomycin at 37 C in a 5% humidified CO2 incubator, and allowed to attach for 4-6 h. The unattached cells were then removed, followed by medium changing to fresh DMEM containing 10% FBS, 100 U/ml penicillin and 100 g/ml streptomycin with addition of indicated concentrations of compounds. Protein preparations-Residues 244 to 476 of human FXRα-LBD (hFXRα-LBD) were subcloned into Nde1/XhoI sites of pET15b to generate N-terminal His-hFXRα-LBD protein expression vector. His-hFXRα-LBD for AlphaScreen assay was purified with a Ni-NTA column followed by a superdex75 column according to the published approach (24). To obtain enough stable protein for crystallization, the plasmid of mutant hFXRα-LBD-C436E/C470E was constructed according to the previously published method (24). The mutant protein was purified by the method similar to that for the wild type His-hFXRα-LBD protein, with the tag removed by incubation with thrombin overnight at 4C. SPR technology-based assay-Binding of NDB to hFXR-LBD was investigated by using surface plasmon resonance (SPR) technology-based Biacore T200 instrument (GE Healthcare). Purified hFXR-LBD protein was immobilized on Series S sensor chip CM5 by the standard primar